Precision Medicine is a disease treatment or prevention strategy that considers which approaches will be effective for which patients based on their genetic, environmental, and lifestyle factors. Targeting patients or groups of patients more accurately for prevention or treatment of a particular disease can spare expense and side-effects. This approach is in contrast to treatments and prevention strategies developed for the average individual but broadly delivered regardless of patient differences.
Despite cutting edge precision medicine technology being prevalent throughout the UK health service, integration of novel technologies for future service delivery and enhancement is still under development. This is due to an inadequate supply of clinical samples, skills shortages and an increased regulatory burden that presents a major barrier for market entry and international trade across the health care system.
CALIN presents the opportunity for appropriate R&D to stimulate innovation and provides skilled personnel to implement formal appraisal and adoption processes overcoming the current challenges.
Precision Medicine within CALIN
Within this theme, CALIN can support clinical, scientific or translational research, with a view to generating new technologies and processes that can be transferred into clinical practice as guidelines, drugs, diagnostic tests or medical devices.
CALIN partners host a range of expertise and facilities enabling the development of precision medicine diagnostics and therapeutics including wearable or minimally invasive devices, antibody drug conjugates and targeted personalised medicine.
Regenerative medicine refers to the process of replacing or regenerating previously irreparable human cells, tissues or organs with a means of restoring or establishing their normal function. This field encompasses a range of disciplines including tissue engineering, gene therapy, molecular biology and biomedical engineering techniques.
Significant support is required to grow the existing regenerative medicine sector and capture external opportunities, which is currently very limited in scope, but is a high value area for growth.
Ireland and Wales have world-leading regenerative medicine research capabilities developing within academia and industry; but routes to commercialisation are not always clear. CALIN can support the translation of regenerative medicine-related academic research into commercial products and provide a clear route to market for new products and services within the theme.
Regenerative Medicine within CALIN
CALIN can offer a range of facilities to enable businesses to carry out their research and development needs in order to produce regenerative medicine products and processes.
CALIN aims to enable the development of commercially viable and clinically effective regenerative medicine applications that are safe and reproducible at an economically acceptable cost. CALIN expertise in this area include cell and tissue repair, tissue engineering and plastics and reconstruction.
Biocompatibility and Safety Evaluation
Biocompatibility and Safety Evaluation explores the interaction of living systems or tissue with materials such as nanoparticles or nanostructured materials, to determine their biologically compatibility.
The nature of materials used in medical devices and any associated drugs have the potential to cause adverse reactions leading to local or systemic responses. Identifying potential reactions is crucial for the safe and sustainable development of life-science materials and technologies.
Furthermore, the level of industrial and research sector work in the field of nanomedicine and nanobiology is rapidly expanding. However, the development of accurate and informative safety evaluation protocols has lagged behind. CALIN can provide the expertise and technology to develop products and services that ensure safe and sustainable nanomaterial and nanotechnology innovations.
Biocompatibility and Safety Evaluation within CALIN
Research within this CALIN theme covers areas including nano-safety and toxicology screening, including biocompatibility testing and the implementation and improvement of new safety evaluation programs and protocols.